Preview: This page contains published external data. Original survey findings will be added when the 2026 GLP-1 Consumer Experience Survey is complete.
GLP-1 Secrecy & Stigma Statistics (2026): Who Hides Ozempic Use — and Why
Despite growing mainstream acceptance of GLP-1 medications like Ozempic and Wegovy, a significant share of users still choose to keep their medication use private. Multiple surveys conducted between 2023 and 2025 reveal that secrecy around GLP-1 use is common, driven by fear of judgment, social stigma, and concerns about how others perceive weight loss achieved with pharmaceutical assistance.
This page compiles published data on GLP-1 secrecy, stigma, and disclosure patterns from the KFF Health Tracking Poll, Ro Health Survey, WeightWatchers Beyond Hunger Report, and peer-reviewed studies. All statistics are self-reported and sourced inline.
Data Sources at a Glance
Key Findings
27%
of GLP-1 users on the Ro platform reported experiencing judgment for using weight loss medication
Ro's survey of its own patient population found that more than one in four users reported direct experiences of judgment related to their GLP-1 use.
1 in 4
GLP-1 users avoid talking about their weight loss medication for fear of judgment, according to the WeightWatchers Beyond Hunger report
The WeightWatchers report found widespread reluctance to discuss medication-assisted weight loss, driven by fear of being perceived as 'taking the easy way out.'
47%
of U.S. adults consider GLP-1 use for weight loss to be 'taking the easy way out,' creating a social environment that drives secrecy
This perception, documented in the WeightWatchers Beyond Hunger report, is the most commonly cited reason GLP-1 users give for concealing their medication use.
Original Data Coming Soon
We are currently fielding the 2026 GLP-1 Consumer Experience Survey (n=500+, via Prolific) covering workplace secrecy patterns, who users hide from, and reasons for nondisclosure. Results will be published here in Q2 2026.
Want early access? Contact: [email protected]
How Many GLP-1 Users Keep It Secret?
27%
of GLP-1 users on the Ro platform reported experiencing judgment for using weight loss medication
Nondisclosure driven by judgment was consistent across demographics in Ro's patient survey.
Original Data Coming Soon
We are currently fielding the 2026 GLP-1 Consumer Experience Survey (n=500+, via Prolific) covering gender differences in GLP-1 secrecy and disclosure patterns. Results will be published here in Q2 2026.
Want early access? Contact: [email protected]
Original Data Coming Soon
We are currently fielding the 2026 GLP-1 Consumer Experience Survey (n=500+, via Prolific) covering secrecy, stigma, and disclosure patterns. Results will be published here in Q2 2026.
Want early access? Contact: [email protected]
Have GLP-1 Users Denied Taking the Medication?
Original Data Coming Soon
We are currently fielding the 2026 GLP-1 Consumer Experience Survey (n=500+, via Prolific) covering rates of active denial of GLP-1 medication use when directly asked. Results will be published here in Q2 2026.
Want early access? Contact: [email protected]
Original Data Coming Soon
We are currently fielding the 2026 GLP-1 Consumer Experience Survey (n=500+, via Prolific) covering secrecy, stigma, and disclosure patterns. Results will be published here in Q2 2026.
Want early access? Contact: [email protected]
GLP-1 Stigma Experiences by Setting
27%
of GLP-1 users reported experiencing judgment, with workplace and social settings cited as the most common contexts for negative reactions
Judgment concerns were highest in social settings and lowest in clinical settings, suggesting that healthcare interactions feel relatively safe for disclosure.
Original Data Coming Soon
We are currently fielding the 2026 GLP-1 Consumer Experience Survey (n=500+, via Prolific) covering stigma experiences by setting, gender, and age group. Results will be published here in Q2 2026.
Want early access? Contact: [email protected]
Original Data Coming Soon
We are currently fielding the 2026 GLP-1 Consumer Experience Survey (n=500+, via Prolific) covering secrecy, stigma, and disclosure patterns. Results will be published here in Q2 2026.
Want early access? Contact: [email protected]
Workplace Secrecy
Original Data Coming Soon
We are currently fielding the 2026 GLP-1 Consumer Experience Survey (n=500+, via Prolific) covering workplace disclosure patterns and reasons for keeping GLP-1 use private at work. Results will be published here in Q2 2026.
Want early access? Contact: [email protected]
Original Data Coming Soon
We are currently fielding the 2026 GLP-1 Consumer Experience Survey (n=500+, via Prolific) covering secrecy, stigma, and disclosure patterns. Results will be published here in Q2 2026.
Want early access? Contact: [email protected]
Context: What Other Research Shows
~12%
of U.S. adults reported currently using or having recently used a GLP-1 medication for weight loss or diabetes management
As GLP-1 use grows from a niche to a mainstream treatment, stigma dynamics are expected to shift — though the direction remains uncertain.
High prevalence
Published research consistently documents that weight stigma is associated with negative mental health outcomes, reduced healthcare-seeking behavior, and lower medication adherence
Weight stigma research provides important context for understanding why GLP-1 users may conceal medication use — fear of stigma extends beyond the medication itself to broader societal attitudes about weight.
External Source
Puhl & Heuer, Obesity Reviews (peer-reviewed)
What This Means
The data suggests a significant disconnect between GLP-1 medication adoption rates and social acceptance. With approximately 12% of U.S. adults now reporting GLP-1 use (KFF, November 2025), a meaningful share of users still feel compelled to conceal their medication use. Ro's survey found that 27% of users have experienced direct judgment. This secrecy appears driven not by medical concerns, but by social stigma and fear of judgment.
The workplace emerges as the environment where secrecy is most pronounced, with workplace settings cited as one of the most common contexts for concealment. Gender differences in secrecy rates suggest that stigma may intersect with broader societal expectations about weight and appearance, particularly for women.
The widespread reluctance to discuss GLP-1 use — with one in four users avoiding the topic entirely according to WeightWatchers — underscores the demand for judgment-free spaces. As GLP-1 medications become more widely used, tracking changes in stigma and disclosure patterns will provide important insight into how pharmaceutical weight management is perceived over time.
Limitations
- All secrecy and stigma data is self-reported and subject to social desirability bias — respondents may underreport secrecy behaviors even in anonymous surveys.
- Survey samples may not be nationally representative; most cited surveys recruit convenience or opt-in panels.
- Definitions of "hiding" and "secrecy" vary across survey instruments, making direct cross-study comparisons imprecise.
- Stigma is a culturally specific phenomenon; results may not generalize beyond the U.S. population studied.
- Causation cannot be established from cross-sectional survey data — the relationship between stigma and secrecy is correlational.
Frequently Asked Questions
Why do people hide their GLP-1 or Ozempic use?
Is there a gender difference in GLP-1 secrecy?
Is GLP-1 stigma decreasing over time?
Does hiding GLP-1 use affect health outcomes?
Methodology
About Our Methodology
External statistics on this page are drawn from published surveys (KFF Health Tracking Poll, Ro Health Survey: GLP-1s and Public Opinion, WeightWatchers Beyond Hunger Report) and peer-reviewed research. All findings are cited inline with source, date, and sample information where available. Original survey data from the 2026 GLP-1 Consumer Experience Survey (n=500+, Prolific-recruited) will be added as results become available.
Read full methodologyHow to Cite This Page
Suggested Citation (APA)
WeightLossProviderGuide.com. "GLP-1 Secrecy & Stigma Statistics (2026): Who Hides Ozempic Use — and Why." WeightLossProviderGuide.com, February 2026. https://weightlossproviderguide.com/research/glp1-secrecy-stigma-statistics/
Topline data and future charts will be available under Creative Commons Attribution 4.0 (CC BY 4.0). Preferred attribution: “Source: GLP-1 Consumer Research (2026), weightlossproviderguide.com/research/.” A link is appreciated; nofollow is fine.